Genexine (095700.KQ) Stock Price

Genexine Price

KRX·CLOSED
2,520.00KRW+105.00 (+4.26 %)
Market closed

Revenue has compounded at 9.0% per year over the past 19 years to 4.57 B KRW. Genexine's net margin stands at -595.0%, down from -129.6% several years earlier. The stock trades about 17% above its 52-week low.

Genexine stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genexine over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genexine stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genexine's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genexine Stock Price History
DateGenexine Price
8/3/20262,520.00 KRW
7/31/20262,415.00 KRW
7/30/20262,340.00 KRW
7/29/20262,285.00 KRW
7/28/20262,350.00 KRW
7/27/20262,450.00 KRW
7/24/20262,475.00 KRW
7/23/20262,410.00 KRW
7/22/20262,340.00 KRW
7/21/20262,355.00 KRW
7/20/20262,330.00 KRW
7/16/20262,350.00 KRW
7/15/20262,325.00 KRW
7/14/20262,160.00 KRW
7/13/20262,315.00 KRW
7/10/20262,415.00 KRW
7/9/20262,310.00 KRW
7/8/20262,325.00 KRW
7/7/20262,425.00 KRW
7/6/20262,475.00 KRW
7/3/20262,440.00 KRW
7/2/20262,455.00 KRW
7/1/20262,530.00 KRW
6/30/20262,510.00 KRW
6/29/20262,635.00 KRW
6/26/20262,270.00 KRW
6/25/20262,505.00 KRW
6/24/20262,550.00 KRW
6/23/20262,515.00 KRW
6/22/20262,650.00 KRW
6/19/20262,760.00 KRW
6/18/20262,885.00 KRW
6/17/20263,195.00 KRW
6/16/20263,050.00 KRW
6/15/20262,995.00 KRW
6/12/20263,005.00 KRW
6/11/20263,020.00 KRW
6/10/20262,990.00 KRW
6/9/20263,010.00 KRW
6/8/20262,840.00 KRW
6/5/20263,340.00 KRW
6/4/20263,490.00 KRW
6/2/20263,495.00 KRW
6/1/20263,530.00 KRW
5/29/20263,660.00 KRW
5/28/20263,855.00 KRW
5/27/20263,855.00 KRW
5/26/20264,005.00 KRW
5/22/20264,175.00 KRW
5/21/20263,910.00 KRW
5/20/20264,100.00 KRW
5/19/20264,240.00 KRW
5/18/20264,365.00 KRW
5/15/20264,760.00 KRW
5/14/20265,010.00 KRW
5/13/20265,040.00 KRW
5/12/20265,190.00 KRW
5/11/20265,350.00 KRW
5/8/20265,300.00 KRW
5/7/20265,200.00 KRW
5/6/20265,120.00 KRW
5/4/20265,250.00 KRW
4/30/20265,430.00 KRW
4/29/20265,600.00 KRW
4/28/20265,710.00 KRW
4/27/20265,740.00 KRW
4/24/20265,680.00 KRW
4/23/20265,950.00 KRW
4/22/20265,720.00 KRW
4/21/20266,080.00 KRW
4/20/20266,520.00 KRW
4/17/20267,100.00 KRW
4/16/20266,560.00 KRW
4/15/20266,390.00 KRW
4/14/20264,995.00 KRW
4/13/20264,875.00 KRW
4/10/20264,860.00 KRW
4/9/20264,635.00 KRW
4/8/20264,615.00 KRW
4/7/20264,595.00 KRW
4/6/20264,620.00 KRW
4/3/20264,630.00 KRW
4/2/20264,535.00 KRW
4/1/20264,760.00 KRW
3/31/20264,630.00 KRW
3/30/20264,875.00 KRW
3/27/20264,990.00 KRW
3/26/20265,020.00 KRW
3/25/20264,750.00 KRW
3/24/20264,565.00 KRW
3/23/20264,365.00 KRW
3/20/20264,660.00 KRW
3/19/20264,575.00 KRW
3/18/20264,765.00 KRW
3/17/20264,815.00 KRW
3/16/20264,825.00 KRW
3/13/20264,885.00 KRW
3/12/20264,760.00 KRW
3/11/20265,020.00 KRW
3/10/20264,920.00 KRW
3/9/20264,860.00 KRW
3/6/20265,080.00 KRW
3/5/20264,660.00 KRW
2/26/20264,435.00 KRW
2/25/20264,560.00 KRW
2/24/20264,515.00 KRW
2/23/20264,605.00 KRW
2/20/20264,455.00 KRW
2/19/20264,510.00 KRW
2/13/20264,420.00 KRW
2/12/20264,585.00 KRW
2/11/20264,640.00 KRW
2/10/20264,710.00 KRW
2/9/20264,500.00 KRW
2/6/20264,420.00 KRW
2/5/20264,630.00 KRW
2/4/20264,730.00 KRW
2/3/20264,760.00 KRW
2/2/20264,820.00 KRW
1/30/20265,040.00 KRW
1/29/20265,330.00 KRW
1/28/20265,130.00 KRW
1/27/20264,980.00 KRW
1/26/20264,870.00 KRW
1/23/20264,595.00 KRW
1/22/20264,280.00 KRW
1/21/20264,285.00 KRW
1/20/20264,465.00 KRW
1/19/20264,285.00 KRW
1/16/20264,370.00 KRW
1/15/20264,415.00 KRW
1/14/20264,445.00 KRW
1/13/20264,510.00 KRW
1/12/20264,550.00 KRW
1/9/20264,470.00 KRW
1/8/20264,510.00 KRW
1/7/20264,570.00 KRW
1/6/20264,645.00 KRW
1/5/20264,780.00 KRW
1/2/20264,890.00 KRW
12/30/20254,685.00 KRW
12/29/20254,705.00 KRW
12/26/20254,635.00 KRW
12/24/20254,680.00 KRW
12/23/20254,720.00 KRW
12/22/20254,830.00 KRW
12/19/20254,815.00 KRW
12/18/20254,700.00 KRW
12/17/20254,805.00 KRW
12/16/20254,890.00 KRW
12/15/20254,965.00 KRW
12/12/20255,030.00 KRW
12/11/20255,100.00 KRW
12/10/20255,010.00 KRW
12/9/20255,070.00 KRW
12/8/20254,950.00 KRW
12/5/20255,040.00 KRW
12/4/20254,995.00 KRW
12/3/20255,100.00 KRW
12/2/20255,000.00 KRW
12/1/20255,030.00 KRW
11/28/20255,180.00 KRW
11/27/20254,965.00 KRW
11/26/20254,995.00 KRW
11/25/20254,890.00 KRW
11/24/20255,030.00 KRW
11/21/20254,915.00 KRW
11/20/20255,060.00 KRW
11/19/20254,800.00 KRW
11/18/20254,825.00 KRW
11/17/20254,965.00 KRW
11/14/20255,130.00 KRW
11/13/20255,200.00 KRW
11/12/20254,960.00 KRW
11/11/20254,630.00 KRW
11/10/20254,895.00 KRW
11/7/20254,860.00 KRW
11/6/20255,240.00 KRW
11/5/20255,210.00 KRW
11/4/20255,120.00 KRW
11/3/20255,030.00 KRW
10/31/20255,180.00 KRW
10/30/20255,070.00 KRW
10/29/20255,170.00 KRW
10/28/20255,400.00 KRW
10/27/20255,310.00 KRW
10/24/20255,170.00 KRW
10/23/20255,200.00 KRW
10/22/20255,240.00 KRW
10/21/20255,240.00 KRW
10/20/20255,270.00 KRW
10/17/20255,190.00 KRW
10/16/20255,280.00 KRW
10/15/20255,460.00 KRW
10/14/20255,570.00 KRW
10/13/20255,850.00 KRW
10/10/20256,160.00 KRW
10/2/20255,680.00 KRW
10/1/20255,370.00 KRW
9/30/20255,520.00 KRW
9/29/20255,710.00 KRW
9/26/20255,090.00 KRW
9/25/20255,120.00 KRW
9/24/20255,190.00 KRW
9/23/20255,630.00 KRW
9/22/20255,500.00 KRW
9/19/20255,470.00 KRW
9/18/20255,410.00 KRW
9/17/20255,340.00 KRW
9/16/20255,400.00 KRW
9/15/20255,430.00 KRW
9/12/20255,580.00 KRW
9/11/20255,600.00 KRW
9/10/20255,560.00 KRW
9/9/20255,580.00 KRW
9/8/20255,570.00 KRW
9/5/20255,470.00 KRW
9/4/20255,540.00 KRW
9/3/20255,220.00 KRW
9/2/20255,160.00 KRW
9/1/20255,070.00 KRW
8/29/20255,160.00 KRW
8/28/20255,490.00 KRW
8/27/20255,210.00 KRW
8/26/20255,180.00 KRW
8/25/20255,170.00 KRW
8/22/20255,120.00 KRW
8/21/20254,980.00 KRW
8/20/20254,940.00 KRW
8/19/20254,900.00 KRW
8/18/20254,980.00 KRW
8/14/20254,970.00 KRW
8/13/20254,935.00 KRW
8/12/20254,875.00 KRW
8/11/20254,940.00 KRW
8/8/20254,985.00 KRW
8/7/20254,905.00 KRW
8/6/20254,960.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Genexine Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
11.30 B KRW
-44.54 B KRW
-16.51 B KRW
Jan 1, 2020
18.54 B KRW
-39.15 B KRW
27.57 B KRW
Jan 1, 2021
36.83 B KRW
-19.10 B KRW
-47.73 B KRW
Jan 1, 2022
16.14 B KRW
-33.68 B KRW
-56.27 B KRW
Jan 1, 2023
4.43 B KRW
-64.28 B KRW
-66.87 B KRW
Jan 1, 2024
2.93 B KRW
-63.84 B KRW
-63.71 B KRW
Jan 1, 2025
4.57 B KRW
-36.07 B KRW
-27.22 B KRW
Jan 1, 2026 (e)
41.41 B KRW
-1.80 T KRW
-2.15 T KRW

Genexine Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:19 PM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITT KRW
EBIT MARGIN%
NET INCOMET KRW
NET INCOME GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
2.666.255.7616.6632.5211.3528.4512.8811.3018.5436.8316.144.432.934.5741.41
146.62134.91-7.93189.4295.24-65.09150.67-54.73-12.2564.0598.61-56.18-72.58-33.7655.97805.53
86.5585.5965.3079.6584.9457.9162.4250.8865.9478.7286.3670.418.74-42.29-8.42-8.42
2.305.353.7613.2727.626.5717.766.557.4514.6031.8111.360.39-1.24-0.39-3.49
-0.01–-0.01-0.01–-0.03-0.03-0.04-0.04-0.04-0.02-0.03-0.06-0.06-0.04-1.80
-247.69-42.92-122.50-31.26-0.29-272.32-94.50-296.19-394.06-211.14-51.86-208.68-1,452.24-2,177.29-788.83-4,358.54
-0.01–-0.01-0.01–-0.03-0.02-0.03-0.020.03-0.05-0.06-0.07-0.06-0.03-2.15
49.81-70.28329.34-17.62-80.762,069.14-37.5176.24-51.54-266.99-273.1117.9118.83-4.74-57.287,812.16
14.0014.0012.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genexine generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genexine retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genexine's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genexine has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genexine's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genexine stock margins

The Genexine margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genexine. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genexine.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
65.94 %
-394.06 %
-146.06 %
Jan 1, 2020
78.72 %
-211.13 %
148.68 %
Jan 1, 2021
86.36 %
-51.86 %
-129.59 %
Jan 1, 2022
70.41 %
-208.69 %
-348.69 %
Jan 1, 2023
8.75 %
-1,452.05 %
-1,510.71 %
Jan 1, 2024
-42.31 %
-2,176.74 %
-2,172.23 %
Jan 1, 2025
-8.43 %
-788.67 %
-595.01 %
Jan 1, 2026 (e)
-8.43 %
-4,358.54 %
-5,199.94 %

Genexine Stock Revenue, EBIT, Earnings per Share

The Genexine earnings per share therefore indicates how much revenue Genexine has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2026 (e)
982.16 KRW
-128,919.29 KRW
-51,071.59 KRW

Genexine business model & stock analysis

Genexine Inc is a leading biotechnology company focused on developing therapies for serious diseases. The company was founded in Korea in 1999 and has since undergone impressive development.

Genexine SWOT Analysis

Strengths

Genexine Inc has developed a strong portfolio of innovative pharmaceutical products that have gained recognition for their effectiveness in treating various diseases.

The company has a skilled and experienced team of researchers and scientists who continue to drive innovation and develop novel therapeutics.

Genexine Inc has established strategic partnerships with leading global pharmaceutical companies, allowing for collaboration and access to additional resources and markets.

Weaknesses

Genexine Inc relies heavily on external partnerships and collaborations, which may pose risks in terms of control over intellectual property rights and potential conflicts of interest.

The company faces significant competition in the pharmaceutical industry, making it essential to continuously invest in research and development to stay ahead.

Genexine Inc may face challenges in navigating regulatory frameworks and obtaining necessary approvals for its products in different markets, leading to potential delays and increased costs.

Opportunities

The pharmaceutical industry is experiencing a growing demand for innovative therapies and treatments, creating opportunities for Genexine Inc to expand its market presence.

Advancements in technology and genomics offer potential for Genexine Inc to develop personalized medicine and targeted treatments, catering to specific patient populations.

Global population growth and aging demographics present an opportunity for Genexine Inc to develop and market products targeting age-related diseases and healthcare needs.

Threats

The pharmaceutical industry is subject to stringent regulations and compliance requirements, which can significantly impact the development, approval, and commercialization of Genexine Inc's products.

Intense competition within the industry, combined with the threat of new market entrants, may pose challenges for Genexine Inc in terms of market share and pricing strategies.

Economic and geopolitical factors can influence market conditions and affect Genexine Inc's ability to expand into new markets or maintain existing operations.

Genexine Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genexine historical P/E ratio, EBIT multiple, and P/S ratio

Genexine annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genexine shares outstanding

The number of shares of Genexine was 14 M in 2025. This indicates how many shares Genexine is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
14.00 M Stocks
Jan 1, 2020
14.00 M Stocks
Jan 1, 2021
14.00 M Stocks
Jan 1, 2022
14.00 M Stocks
Jan 1, 2023
14.00 M Stocks
Jan 1, 2024
14.00 M Stocks
Jan 1, 2025
14.00 M Stocks
Jan 1, 2026 (e)
14.00 M Stocks

Genexine stock splits

In Genexine's history, there have been no stock splits.
Price targets and forecasts for Genexine are not yet available.

Genexine Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/13/2024231.29KRW-9.09 BKRW-2024 Q1
2/8/2024-229.25KRW-2.02 BKRW-2023 Q4
8/14/2023-612.24KRW-1.01 BKRW-2023 Q2
5/15/2023642.71KRW-26.39 BKRW-2023 Q1
2/16/2023-1,295.89KRW-1.01 BKRW-2022 Q4
11/14/2022-196.14KRW-0.00KRW-2022 Q3
8/16/2022-234.23KRW-0.00KRW-2022 Q2
5/4/2022236.34KRW-9.14 BKRW-2022 Q1
2/18/2021-645.16KRW--KRW-2020 Q4
11/5/2020-373.23KRW--KRW-2020 Q3

Genexine shareholder structure

% Name
2.26906%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.56176%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.10535%
State Street Global Advisors (US)
State Street Global Advisors (US)
0.09451%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.00569%
DFA Australia Ltd.
DFA Australia Ltd.
0.00565%
American Century Investment Management, Inc.
American Century Investment Management, Inc.

Genexine Beneficial Ownership Filings (SEC 13D/G)

Free Float
74.5%
Float Shares
-
Shares Outstanding
-

Genexine Executives and Management Board

14 members · avg. age 61 · 0 % women

Management

JW

Mr. Jeong Won Woo (63)

President, Director · since 2021

–
SH

Mr. Seong Jun Hong (58)

Chief Executive Officer, Chief Financial Officer, Vice President, Director · since 2021

–
JL

Mr. Jang Hui Lee (60)

Managing Director

–
SB

Mr. Seong Gi Baek (73)

Internal Auditor

–
MH

Mr. Min Gyu Huh (47)

Assistant Managing Director

–
HJ

Mr. Hyeon Cheol Jeon (64)

Internal Auditor

–

Board of Directors

YS

Mr. Yeong Cheol Sung (66)

Chairman of the Board · since 2021

2.13 B KRW
YK

Mr. Yeong Jin Kim (65)

Other Non-Executive Director

–
HL

Mr. Hyeok Jong Lee (53)

Other Non-Executive Director · since 2021

–
JB

Mr. Jin Geon Bae (70)

Non-Executive Independent Director

–
PL

Mr. Peter Laivins (63)

Non-Executive Independent Director

–
US

Mr. Ui Cheol Shin (51)

Non-Executive Independent Director

–

Genexine Supply Chain

Genexine Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Nameβ 1YTrend
1
Merck & Co
Supplier·Customer·Pharmaceuticals·US
0.64
-0.31
-0.89
-0.82
-0.55
—
-0.17
2
GenNBio
Supplier·Customer·Commercial Services & Supplies·KR
0.53
0.81
0.82
0.82
0.83
—
—
3
Binex
Supplier·Customer·Pharmaceuticals·KR
0.30
0.77
0.75
-0.06
0.81
—
0.60
4
Ajinomoto
Supplier·Customer·Food Products·JP
0.20
0.80
0.58
0.42
-0.68
—
-0.43
5
NeoImmuneTech KDR
Supplier·Customer·Biotechnology·US
0.11
0
-0.55
0.53
—
—
—

Frequently asked questions about Genexine

The business model of Genexine Inc involves the development and commercialization of innovative biopharmaceutical products. Genexine focuses on the research and development of novel immunotherapeutics and long-acting biologics, including therapeutic DNA vaccines and recombinant protein-based drugs. Their goal is to address critical unmet medical needs and provide effective treatment options for patients. By leveraging their expertise in genetic engineering and biotechnology, Genexine aims to contribute to the advancement of healthcare and enhance patients' quality of life through the development of cutting-edge therapeutics.

Genexine Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Genexine Inc in the market include other companies operating in the biotechnology and pharmaceutical industries. Some notable competitors include Celltrion Inc, Samsung Biologics, and Hanmi Pharmaceutical Co. These companies also focus on developing and commercializing innovative drugs, therapies, and biologics, which creates a competitive landscape for Genexine Inc in the market.

Genexine Inc is a reputable biotechnology company with a rich history and background. Established in 1999, Genexine has since emerged as a leading player in the field of genetic medicine. The company specializes in developing innovative and effective therapeutics using its cutting-edge platform technologies. Genexine has successfully advanced several clinical candidates that target various diseases, including cancer, infectious diseases, and immune disorders. With a strong focus on research and development, Genexine has gained recognition for its robust pipeline and collaborations with global pharmaceutical companies. As a result, Genexine Inc has established itself as a trusted name in the biotech industry, dedicated to improving patient lives through advanced medical innovation.

Genexine Inc has achieved several significant milestones in its history. These include successful completion of clinical trials for their pipeline products, securing strategic partnerships with renowned pharmaceutical companies, and obtaining regulatory approvals for commercialization. Genexine has also received recognition for its innovative research and development efforts, resulting in numerous patent grants. Additionally, the company has successfully raised capital through public offerings and private placements to support its growth strategy and further advance its portfolio. Through these milestones, Genexine Inc has demonstrated its commitment to advancements in the field of biotechnology and its dedication to improving patient outcomes.

Genexine Inc is primarily present in South Korea, where its headquarters are located.

Genexine Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. The company is committed to developing cutting-edge therapeutics and vaccines to address unmet medical needs. With a focus on research and development, Genexine strives to improve the quality of life for patients worldwide. The company's corporate philosophy emphasizes integrity, transparency, and a patient-centric approach. Genexine Inc aims to create sustainable growth by fostering strong partnerships and expanding its pipeline of innovative drug candidates. With its commitment to scientific advancement and strong corporate values, Genexine Inc is poised to make significant contributions to the biotech industry.

6 analysts currently rate the Genexine stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Genexine to generate revenue of 41.41 B KRW and earnings per share of -153,806.84 KRW.

Genexine Analyst Price Targets 2026

Converted at the current exchange rate, the Genexine share trades at 1.53 EUR (2,520.00 KRW).

Genexine Inc is an emerging biotechnology company based in South Korea. Its goal is to develop and market innovative, highly effective therapies for a variety of diseases. The company has a wide portfolio of products and services focused on three main areas: therapeutics, vaccines, and diagnostics. In the therapeutics field, Genexine focuses on the development of biopharmaceuticals that can be used to treat cancer, autoimmune diseases, and other serious conditions. The company has several potential products in the pipeline, including GX-I7, an immunotherapy for the treatment of metastatic breast cancer, and GX-188E, a DNA vaccine for the treatment of HPV-related cervical cancer. Genexine is also involved in the development of vaccines that can be used to combat infectious diseases such as HPV, influenza, and COVID-19. The company has collaborated with other biotech companies and scientists to develop COVID-19 vaccines that are currently undergoing clinical trials. In addition to therapeutics and vaccines, Genexine also offers diagnostic services. The company has a proprietary technology platform called Polyplex, which can be used for the production of DNA and RNA vaccines, as well as disease diagnosis. By utilizing this technology platform, Genexine can perform accurate and rapid diagnoses of infectious diseases and be able to produce tailored vaccines. Genexine also works closely with other biotechnology companies and academic research institutions. For example, the company has announced a collaboration with BioNTech to develop an mRNA vaccine platform for cancer immunotherapy. The company has also signed a cooperation agreement with the Cleveland Clinic to develop new and innovative therapies for the treatment of cancer and autoimmune diseases. In terms of funding, Genexine enters into strategic partnerships to support the development of its products and services. The company has a business partnership with Chinese company Qilu Pharmaceutical to further develop and market its cancer therapeutics GXNPC. Genexine has also made an agreement with Korean company ToolGen to further develop and market its Polyplex technology platform. Overall, Genexine's business model is focused on developing and bringing to market innovative, highly effective products that can contribute to improving the health and well-being of people worldwide. Through collaboration with strategic partners and a commitment to groundbreaking research and development, Genexine aims to become a leading biotechnology company in the coming years.

The expected revenue of Genexine is 41.41 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genexine is -2.15 T KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genexine is currently -0.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genexine stock.

The price-to-sales ratio (P/S) of Genexine is currently 0.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genexine stock.

The Eulerpool Quality Score for Genexine is 2/10.

The ISIN of Genexine is KR7095700001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Genexine is 095700.KQ. The ticker symbol is used to trade Genexine shares on the stock exchange.

Genexine paid dividends every year for the past 0 years.

Genexine is assigned to the 'Health' sector.

The dividends of Genexine are distributed in KRW.

All fundamentals and in-depth analysis of Genexine

Our stock analysis for Genexine stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genexine. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genexine Stock
Genexine Revenue→
Genexine Stock
Genexine Net Income→
Genexine Stock
Genexine P/E→
Genexine Stock
Genexine P/S→
Genexine Stock
Genexine EBIT→
Genexine Stock
Genexine Dividend→
Genexine Stock
Genexine Directors Dealings→
Genexine Stock
Genexine Stocks→
Genexine Stock
Genexine Market capitalization→
Genexine Stock
Genexine Debt→
Genexine Stock
Genexine Liabilities→
Genexine Stock
Genexine Equity→
Genexine Stock
Genexine AAQS→
Genexine Stock
Genexine Employees→
Genexine Stock
Genexine ROE→
Genexine Stock
Genexine ROA→
Genexine Stock
Genexine ROCE→
Genexine Stock
Genexine News→
Genexine Stock
Genexine Analyst Price Targets→

Health Stocks

GenfitGenex PharmaceuticalGenflow BiosciencesGenetics Generation AdvancementGenincodeGenetic TechnologiesGeninusGenetic SignaturesGenmab ASGeneSystem CoGenMont BiotechGenesis IBRC IndiaAll Stocks A–Z →